Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash & Current Investments (2021 - 2025)

Kiniksa Pharmaceuticals International's Cash & Current Investments history spans 5 years, with the latest figure at $414.1 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 69.96% year-over-year to $414.1 million; the TTM value through Dec 2025 reached $414.1 million, up 69.96%, while the annual FY2025 figure was $414.1 million, 69.96% up from the prior year.
  • Cash & Current Investments reached $414.1 million in Q4 2025 per KNSA's latest filing, down from $529.3 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $529.3 million in Q3 2025 to a low of $145.6 million in Q1 2022.
  • Average Cash & Current Investments over 5 years is $249.5 million, with a median of $216.2 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: plummeted 44.91% in 2022, then soared 74.15% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $182.2 million in 2021, then increased by 4.61% to $190.6 million in 2022, then grew by 8.27% to $206.4 million in 2023, then grew by 18.05% to $243.6 million in 2024, then skyrocketed by 69.96% to $414.1 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Cash & Current Investments are $414.1 million (Q4 2025), $529.3 million (Q3 2025), and $307.8 million (Q2 2025).